Heron Therapeutics, Inc. (HRTX) Earnings Call Transcripts
Heron Therapeutics, Inc.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Heron Therapeutics reported net revenues of $34.7 million, slightly below expectations due to seasonal headwinds and severe weather impacting elective surgeries. The company maintained its full-year guidance of $173 million to $183 million in net product sales and adjusted EBITDA of $10 million to $20 million. Management highlighted a strong recovery in March with net sales exceeding $15 million, indicating potential for improved performance in the upcoming quarters.
Reported metrics
| Metric | Value |
|---|---|
| Net Revenue | $34.7 million (miss) |
| Gross Margin | 69% (negative) |
| Adjusted EBITDA | -$727,000 (miss) |
| ZYNRELEF Revenue Growth | 27% (positive) |
| APONVIE Revenue Growth | over 50% (positive) |
| CINVANTI Market Share | 25% (inline) |
Guidance from management
Heron maintained its full-year guidance for net product sales between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, indicating confidence in recovery as elective procedures are rescheduled throughout the year.
What management said
Brandon, thank you for the questions. I'll start with the Baxter settlement, and then I'll turn it to Mark. Look, based on the terms of the settlement, we really can't go into the details of that other than to say that the dates and everything that have been published. But outside of that, we're just forbidden from saying anything on that. So I'll turn it over to Mark to talk about the ZYNRELEF questions that you ask...
What analysts pressed on
Analysts expressed concerns regarding the impact of severe weather on surgical volumes and how this might affect future sales. There were also questions about the effectiveness of the IGNITE program and how management plans to overcome adoption friction for ZYNRELEF and APONVIE.
Main topics on the call
- Revenue Performance — Heron reported total net sales of $34.7 million for Q1 2026, which reflects a decline attributed to seasonal factors and weather disruptions. CEO Craig Collard noted, "January was our most difficult month since I joined ...
- Acute Care Portfolio Growth — The Acute Care portfolio saw a revenue growth of 32% year-over-year, with ZYNRELEF growing 27% and APONVIE growing over 50%. Collard stated that the IGNITE program has been a key growth driver for ZYNRELEF, which is expe...
- Sales Force Expansion — Heron plans to expand its sales force in Q3 2026, which is viewed as a significant catalyst for growth. Management expressed confidence that this expansion will enhance market share for both ZYNRELEF and APONVIE.
- CINVANTI Market Stability — CINVANTI maintained a stable market share of 25% in the NK1 category despite competitive pressures. Management highlighted that the product's performance has remained resilient, with a consistent customer base and new ac...
Read the full Heron Therapeutics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (HRTX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 25 calls on record spanning June 17, 2020 to August 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 25 Heron Therapeutics, Inc. earnings call transcripts on record, spanning June 17, 2020 to August 10, 2026. Based on this history, Heron Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- HRTX
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 25
- First call
- June 17, 2020
- Most recent
- August 10, 2026
- Reporting cadence
- quarterly